“In vitro” 3D models of tumor-immune system interaction

Interaction between cancer cells and immune system critically affects development, progression and treatment of human malignancies. Experimental animal models and conventional “in vitro” studies have provided a wealth of information on this interaction, currently used to develop immune-mediated ther...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2014-12, Vol.79-80, p.145-154
Main Authors: Hirt, Christian, Papadimitropoulos, Adam, Mele, Valentina, Muraro, Manuele G., Mengus, Chantal, Iezzi, Giandomenica, Terracciano, Luigi, Martin, Ivan, Spagnoli, Giulio C.
Format: Article
Language:English
Subjects:
Animals
Cancer
Cell Culture Techniques
Cell Differentiation
Cell Hypoxia - immunology
Cytokines - immunology
Disease Progression
Humans
Hypoxia
Immune system
In Vitro Techniques
Lactic Acid - metabolism
Models, Biological
Neoplasms - immunology
Neoplasms - pathology
Neoplasms - therapy
Perfusion bioreactors
Three-dimensional cultures
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interaction between cancer cells and immune system critically affects development, progression and treatment of human malignancies. Experimental animal models and conventional “in vitro” studies have provided a wealth of information on this interaction, currently used to develop immune-mediated therapies. Studies utilizing three-dimensional culture technologies have emphasized that tumor architecture dramatically influences cancer cell–immune system interaction by steering cytokine production and regulating differentiation patterns of myeloid cells, and decreasing the sensitivity of tumor cells to lymphocyte effector functions. Hypoxia and increased production of lactic acid by tumor cells cultured in 3D architectures appear to be mechanistically involved. 3D culture systems could be further developed to (i) include additional cell partners potentially influencing cancer cell-immune system interaction, (ii) enable improved control of hypoxia, and (iii) allow the use of freshly derived clinical cancer specimens. Such advanced models will represent new tools for cancer immunobiology studies and for pre-clinical assessment of innovative treatments. [Display omitted]
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2014.05.003